Thermo Fisher

Covid-19 development round-up: February 25, 2022

The state of the fight: 

Sanofi and GSK’s vaccine candidate demonstrated 58% efficacy against symptomatic Covid-19 in Phase 3.
  Hetero Pharma’s generic version of Merck’s molnupiravir reduced the risk of hospitalization by over 65%.
  Britain and Japan pledged a combined $514 million to CEPI’s pandemic preparedness plan.   AUTHORIZED VACCINES

 
The U.S. FDA lifted its clinical hold on Bharat Biotech’s Covaxin, clearing the way for the inactivated vaccine…

Mentions:
Covid-19, vaccines, drugs, Bharat Biotech, FDA, Ocugen, Pfizer, BioNTech, CDC, Medicago, GSK, Moderna, Gamaleya Institute, CNBG, Sinopharm, EMA, CanSino, Anhui Zhifei Longcom, Sanofi, Thermo Fisher, Valneva, CEPI, AstraZeneca, Sinovac, Africa CDC, COVAX, WHO, J&J, Vir, Merck, Gilead, Shionogi, Suzhou Abogen, Walvax
Read more
Thermo Fisher bets $1.9B on PeproTech

Thermo Fisher wrapped up 2021 by buying bioscience reagents specialist PeproTech for $1.9 billion in cash, the Massachusetts-based behemoth announced last week.

The deal gives Thermo Fisher access to New Jersey-based PeproTech’s recombinant proteins portfolio, “an excellent strategic fit within our biosciences business,” per the press release.

Mentions:
Thermo Fisher, M&A
Read more
Covid-19 development round-up: December 9, 2021

The state of the fight: 

New studies supported heterologous primary regimens and heterologous boosters.
  Serum Institute of India is weighing slashing Covishield production by 50%.
  The U.S. FDA OK’d AstraZeneca’s Evusheld long-acting monoclonal antibody therapy as PrEP for certain groups.

 

AUTHORIZED VACCINES  

Mixing the AstraZeneca/Oxford or Pfizer/BioNTech vaccines with a second dose of Moderna’s shot generated non-inferior immune responses…

Mentions:
Covid-19, vaccines, drugs, AstraZeneca, Pfizer, BioNTech, Moderna, Novavax, Finlay Institute, Gamaleya Institute, CureVac, J&J, Janssen, Valneva, EMA, Bavarian Nordic, Sinovac, CEPI, SII, Gavi, COVAX, Africa CDC, WHO, World Bank, UNICEF, Zydus Cadila, Thermo Fisher, Merck, FDA, GSK
Read more
Thermo Fisher shells out $17.4B for PPD

Thermo Fisher announced last week that it will buy North Carolina-based clinical research organization PPD for $17.4 billion in cash and approximately $3.5 billion in assumed debt.

In a boost to its pharma services business, the Massachusetts-based company will acquire PPD’s drug development platform, patient recruitment capabilities and laboratory services, the press release said.

The deal is one of several acquisitions for Thermo Fisher this year and, according to STAT, its…

Mentions:
Thermo Fisher, PPD, M&A, drugs
Read more
Covid-19 development round-up: March 12, 2021

The state of the hunt:

J&J’s vaccine became the first single-dose Covid-19 jab to receive EUL from the World Health Organization.
  A growing list of countries—including at least one COVAX AMC participant—suspended their rollouts of AstraZeneca’s vaccine over safety concerns.
  Monoclonal antibodies from Lilly and a separate mAb from GSK and Vir substantially cut the risk of hospitalization or death in people with mild or moderate Covid-19 at high risk of…
Mentions:
Covid-19, vaccines, drugs, J&J, EUL, WHO, COVAX, COVAX AMC, AstraZeneca, Lilly, GSK, Vir, Janssen, EC, EMA, Moderna, NIAID, Takeda, Pfizer, BioNTech, Oxford University, BBIL, Gamaleya Institute, Sinovac, Novavax, Sanofi, Translate Bio, Bavarian Nordic, Adaptvac, Aspen Pharmacare, Terumo, Fiocruz, Baxter Biopharma Solutions, SII, Adienne Pharma, RDIF, CNBG, Sinopharm, Thermo Fisher, Inovio, Novasep, CanSino, CEPI, VBI Vaccines, SK Bioscience, DCVMN, ACT Accelerator, Wellcome Trust, UNITAID, IADB, KCDA, Gilead, NIH, Roche, Merck, Ridgeback, Novartis, Molecular Partners, Sorrento Therapeutics
Read more
Covid-19 development round-up: January 22, 2021

The state of the hunt:

COVAX has inked a deal for up to 40 million doses of Pfizer/BioNTech’s vaccine.
  India launched its mass vaccination campaign against Covid-19.
  China and India are both giving away vaccine doses to their neighbors.

 

Vaccines


Approved or authorized vaccines
 
China’s Sinovac jab more effective using three-week interval: A silver lining has emerged to last week’s middling news from the Butantan Institute’…

Mentions:
Covid-19, vaccines, drugs, diagnostics, COVAX, Pfizer, BioNTech, Sinovac, Butantan Institute, EU, EMA, União Química Farmacêutica Nacional, Gamaleya Institute, AstraZeneca, Dr. Reddy’s, BBIL, Moderna, Takeda, CNBG, Sinopharm, Novavax, Emergent, J&J, Janssen, Chumakov Center, iosBio, ImmunityBio, Vector Institute, EuBiologics, WUSTL, Gritstone Oncology, NIAID, ConserV Bioscience, LLNL, UN, WHO, COVAX Facility, EC, Gavi, AU, SII, Biovac, Bayer, CureVac, EUL, Oxford, CanSino, UNICEF, Africa CDC, CDC, Lilly, FDA, NIH, Roche, Turn Therapeutics, Faron Pharmaceuticals, DoD, Jemincare, AvantGen, IGM Biosciences, FIND, UNITAID, Premier Medical, Thermo Fisher, Mesa Biotech
Read more
Thermo Fisher, Fujifilm boost manufacturing

Massachusetts-based Thermo Fisher announced last week its $877 million all-cash acquisition of Novasep’s Belgian viral vector manufacturing business, Henogen. The purchase will help Thermo Fisher “expand its capabilities for cell and gene vaccines and therapies globally,” the press release said.

Fellow CDMO Fujifilm Diosynth Biotechnologies also has new manufacturing muscle in the works. Fujifilm and its collaborator, the Massachusetts Center for Advanced Biological Innovation and…

Mentions:
Thermo Fisher, Novasep, Henogen, vaccines, drugs, CDMOs, Fujifilm Diosynth, Fujifilm, CABIM, R&D, gene editing, gene therapy
Read more
Pharma capacity investments continue

Two companies last week extended a veritable frenzy of recent industry capacity enhancement announcements.

Massachusetts-based Thermo Fisher said it will expand its sterile drug development and commercial manufacturing facilities—including live virus, aseptic liquid and lyophilized vial filling capabilities—in North Carolina, the United Kingdom and Italy. The expansions are in addition to new facilities in Singapore and China the company already announced, the press release said.

…
Mentions:
Thermo Fisher, vaccines, Merck, R&D
Read more
Covid-19 development round-up: December 11, 2020

The state of the hunt:

Pfizer/BioNTech’s vaccine won U.S. FDA Emergency Use Authorization.
  The inactivated vaccine from CNBG’s Beijing subsidiary secured UAE registration.
  Bharat Biotech and SII requested Indian authorization of their respective jabs.

 

Vaccines


Approved or authorized vaccines
 
The Pfizer/BioNTech vaccine extended its regulatory lead this week with new authorizations, including a U.S. nod.
 
The…

Mentions:
Covid-19, vaccines, drugs, diagnostics, Pfizer, BioNTech, FDA, CNBG, Sinopharm, BBIL, SII, EMA, WHO, AstraZeneca, Moderna, Gamaleya Institute, Sinovac, Sino Biopharma, J&J, Janssen, Anges, Inovio, Roche, IMBCAS, University of Queensland, CSL, CEPI, Sanofi, GSK, WUSTL, Gennova, Tonix, SK Bioscience, EuBiologics, KMPC, Providence Therapeutics, Health Canada, BioE, OSU, COVAX AMC, Schott Kaisha, SGD Pharma India, Hindustan Syringes, Snowman, Instituto Butantan, Halix, Duke University, RDIF, Shenzhen Kangtai, CureVac, Fareva, ADB, CDC, Dulas, DHL, Amnesty International, Oxfam, People’s Vaccine, Novavax, IAVI, Lilly, Gilead, APEIRON, Cyxone, Sorrento, University of Louisville, AbCellera, Quest Diagnostics, LabCorp, NIH, QIAGEN, Thermo Fisher, BMGF, WTO
Read more
Covid-19 development round-up: September 25, 2020

The state of the hunt:

Vaccine candidates from Novavax and J&J’s Janssen subsidiary entered Phase 3.
  Chinese regulators are reviewing inactivated vaccine candidates from CNBG for conditional authorization.
  Fujifilm’s flu drug Avigan (favipiravir) met its primary endpoint in a Phase 3 trial for treatment of Covid-19.

 

Vaccines

Phase 3 candidates:
 
China weighs approval of CNBG shots: State regulators are reviewing CNBG’s two…

Mentions:
Covid-19, vaccines, drugs, diagnostics, Novavax, J&J, Janssen, CNBG, Fujifilm Toyama, SII, AstraZeneca, Petrovax, CanSino, Bharat Biotech, BBIL, Codagenix, Clover Pharmaceuticals, Vector Research Center, COVAX, Gavi, Sanofi, GSK, Moderna, SiO2, ReiThera, Valneva, Endo, Technovalia, BioNet, Mymetrics, Precision Biologics, Inovio, Pfizer, Vir Biotechnology, Fiocruz, BCG, Gilead, Hovione, Ligand, ChemRar, RDIF, Relief Therapeutics, NeuroRx, Lumen Bioscience, OncoImmune, Humanigen, Thermo Fisher, SynAct Pharma, Sorrento Therapeutics, Mylan, Ortho, Luminex, Diomics, NIH, BARDA, FDA
Read more
Subscribe to Thermo Fisher